BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.7.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20180311T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20181104T060000
END:STANDARD
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20181205T130000
DTEND;TZID=America/New_York:20181205T140000
DTSTAMP:20261008T192156
CREATED:20181105T160248Z
LAST-MODIFIED:20181106T104647Z
UID:18240-1544014800-1544018400@senzagen.com
SUMMARY:Open Webinar on Respiratory Sensitization by SenzaGen
DESCRIPTION:In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARD™ technology platform \nA seminar given on two occasion. This one targeted forthe US audience at 13:00 EST  (19:00 CET) \nThe presentation will give insight into the latest in vitro technology for identifying respiratory sensitizers using human dendritic-like cell lines and genomics.  A thorough explanation of the GARD™ platform will be covered as well as its versatility and reliability for safety assessment applicable to all industries. Sensitization testing with GARD™ is based on functional genomics. \nThe presentation will cover: \n\nDevelopment of the genomic-based GARD™ test platform for skin sensitization hazard\, potency classification\, and now also respiratory sensitization.\nDendritic cells – why they are also relevant for respiratory sensitization.\nGene mapping – what genes are in the assay\, and how are they relevant for sensitization.\nHow GARD™ can discriminate between skin and respiratory sensitization and why this is relevant.\nUpdate on the development of the SenzaGen R&D pipeline including GARD™ for materials – testing medical devices\, GARD™ for proteins – classification of protein sensitizers\, GARD™ for mixtures – assessment of complex formulations and Unknown or Variable Composition UVCBs.\n\n  \nNext generation in vitro skin and respiratory sensitization testing using genomics with GARD™ \nThe GARD™ platform is a versatile in vitro testing strategy which currently consist of three assays targeting two toxicological endpoints: skin sensitization (GARDskin & GARDpotency) and respiratory sensitization (GARDair). These assays make use of unique genomic biomarker signatures comprising genes involved in pathways known to be immunologically relevant to the sensitization process. Supported by modern technologies for pattern recognition\, the large informational content provided by this approach enable for mechanism-of-action based decisions\, which becomes evident in a consistently high predictive accuracy \n\nDon’t miss the opportunity to learn more from our researchers. Welocome to join! \nREGISTER HERE \n  \n 
URL:https://senzagen.com/event/open-webinar-on-respiratory-sensitization-by-senzagen-2/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2018/11/Webinar_Logo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20181204T150000
DTEND;TZID=Europe/Stockholm:20181204T160000
DTSTAMP:20261008T192156
CREATED:20181105T160230Z
LAST-MODIFIED:20181106T104722Z
UID:18231-1543935600-1543939200@senzagen.com
SUMMARY:Open Webinar on Respiratory Sensitization by SenzaGen
DESCRIPTION:In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARD™ technology platform \nA seminar given on two occasions\, this one targeted for the EUROPEAN time zone \nThe presentation will give insight into the latest in vitro technology for identifying respiratory sensitizers using human dendritic-like cell lines and genomics.  A thorough explanation of the GARD™ platform will be covered as well as its versatility and reliability for safety assessment applicable to all industries. Sensitization testing with GARD™ is based on functional genomics. \nThe presentation will cover: \n\nDevelopment of the genomic-based GARD™ test platform for skin sensitization hazard\, potency classification\, and now also respiratory sensitization.\nDendritic cells – why they are also relevant for respiratory sensitization.\nGene mapping – what genes are in the assay\, and how are they relevant for sensitization.\nHow GARD™ can discriminate between skin and respiratory sensitization and why this is relevant.\n\nUpdate on the development of the SenzaGen R&D pipeline including GARD™ for materials – testing medical devices\, GARD™ for proteins – classification of protein sensitizers\, GARD™ for mixtures – assessment of complex formulations and Unknown or Variable Composition UVCBs. \n  \nNext generation in vitro skin and respiratory sensitization testing using genomics with GARD™\nThe GARD™ platform is a versatile in vitro testing strategy which currently consist of three assays targeting two toxicological endpoints: skin sensitization (GARDskin & GARDpotency) and respiratory sensitization (GARDair). These assays make use of unique genomic biomarker signatures comprising genes involved in pathways known to be immunologically relevant to the sensitization process. Supported by modern technologies for pattern recognition\, the large informational content provided by this approach enable for mechanism-of-action based decisions\, which becomes evident in a consistently high predictive accuracy. \nDon’t miss the opportunity to learn more from our researchers. Welcome to join! \nREGISTER HERE
URL:https://senzagen.com/event/open-webinar-on-respiratory-sensitization-by-senzagen/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2018/11/Webinar_Logo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20181129T080000
DTEND;TZID=Europe/Stockholm:20181129T170000
DTSTAMP:20261008T192156
CREATED:20181029T130514Z
LAST-MODIFIED:20181029T151616Z
UID:18108-1543478400-1543510800@senzagen.com
SUMMARY:EUROFINS Human Safety Seminar - in vitro Toxicology at a Glance. Today's Challenges\, Solutions & Future Developments
DESCRIPTION:Dr Andy Forreryd is one of three speakers at the Human Safety Seminar organised by Eurofins BioPharma Product Testing Munich where he is to present the GARD platform for skin and respiratory sensitization  \nTopics for the seminar:  \n\nIn vitro Methods to test for Endocrine Disrupting Properties  \nIn vitro Skin sensitization – Challenges to Overcome \nEye Irritation ex vivo and in vitro methods – Current status \nGARD platform\, genomic test for skin and respiratory sensitization with potency classification  \nNew Developments in Genotoxicity Testing for Chemicals\, Cosmetics and Pharmaceuticals – in vitro and in vivo Comet Assay \n\nFor more information and registration  \nhttps://www.eurofins.com/human-safety-seminar
URL:https://senzagen.com/event/eurofins-human-safety-seminar-in-vitro-toxicology-at-a-glance-todays-challenges-solutions-future-developments/
LOCATION:Eurofins Munich\, Robert-Koch-Straße 3a\, Planegg
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2018/10/save-the-date_final_web.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181127
DTEND;VALUE=DATE:20181129
DTSTAMP:20261008T192156
CREATED:20181029T144439Z
LAST-MODIFIED:20181031T092502Z
UID:18057-1543276800-1543449599@senzagen.com
SUMMARY:SFT - Société Francaise de Toxicologie
DESCRIPTION:En 2018\, le congrès annuel de la SFT a lieu à Lille\, les 27 et 28 novembre\, espace Jeanne de Flandre (Lille Grand Palais). \nPoster\nGARD® – in vitro safety assessment of skin and respiratory sensitizers using a genomics-based platform \nMeet Anna Cherouvrier Hansson at the conference. To book a meeting\, please email: anna.c.hansson (at) senzagen.com
URL:https://senzagen.com/event/sft-societe-francaise-de-toxicologie/
LOCATION:Lille Grand Palais\, France
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2018/10/logo_sft.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181127
DTEND;VALUE=DATE:20181130
DTSTAMP:20261008T192156
CREATED:20180911T085055Z
LAST-MODIFIED:20181102T123937Z
UID:17541-1543276800-1543535999@senzagen.com
SUMMARY:Biocompatibility for Medical Devices\, Barcelona\, Spain
DESCRIPTION:SenzaGen is participating at the Biocompatibility for Medical Devices\, Barcelona. \nUpdates and changes to the ISO 10993 standards\, regulatory updates and case studies of how to use ISO 10993 for evaluation of Medical Devices\nISO 10993: ARE YOU BIOCOMPATIBLE?\nRisk Mitigation. Chemical Characterisation. Practical Implementation. \n  \nMeet our Medical Device experts Rose-Marie Jenvert and Joshua Schmidt  at the conference! \nTo book a meeting\, please email them\nrose-marie.jenvert (a) senzagen.com\njoshua.schmidt (a) senzagen.com
URL:https://senzagen.com/event/biocompatibility-for-medical-devices-barcelona-spain/
LOCATION:Barcelona\, Spain
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2018/05/Biocompatibility-for-Medical-Devices-logo-COLOR-5ba41af89b878f0aae531e1751febc8a.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181105
DTEND;VALUE=DATE:20181108
DTSTAMP:20261008T192156
CREATED:20180911T084622Z
LAST-MODIFIED:20180911T084634Z
UID:17535-1541376000-1541635199@senzagen.com
SUMMARY:Bio Europe\, Copenhagen\, Denmark
DESCRIPTION:24th annual conference
URL:https://senzagen.com/event/bio-europe-copenhagen-denmark/
LOCATION:Copenhagen\, Denmark
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2018/05/BEU18-Logos-NEW-05-999add75136ab900b4a4c046561f6920.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181104
DTEND;VALUE=DATE:20181108
DTSTAMP:20261008T192156
CREATED:20181029T172737Z
LAST-MODIFIED:20181029T172737Z
UID:18092-1541289600-1541635199@senzagen.com
SUMMARY:ACT 2018 – American College of Toxicology Annual Meeting
DESCRIPTION:SenzaGen is participating at The American College of Toxicology 2018 Annual Meeting that will be held Nov. 4-7 in West Palm Beach. \nThis year’s meeting will feature lectures\, poster sessions\, and other events for today’s toxicologists to network with each other and hone their skills. \nFor more information on ACT 2018\, please visit www.actox.org.
URL:https://senzagen.com/event/act-2018-american-college-of-toxicology-annual-meeting/
LOCATION:Palm Beach County Convention Center
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2018/10/ACT-hp-slider4inner2f.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181031
DTEND;VALUE=DATE:20181102
DTSTAMP:20261008T192156
CREATED:20181029T150050Z
LAST-MODIFIED:20181031T091912Z
UID:18119-1540944000-1541116799@senzagen.com
SUMMARY:Medical Design & Manufacturing (MD&M) Minneapolis
DESCRIPTION:SenzaGen is present at the\nMedical Design & Manufacturing (MD&M) Minneapolis \nThe MD&M Minneapolis Conference is the region’s largest educational offering of its kind\, taking place in North America’s second largest hub for medical device innovation — the Midwest. This year’s conference lineup features a curated roster of speakers with deeply technical expertise in everything from product development and quality to 3D printing and next-gen design. \nMedical Design & Manufacturing (MD&M) Minneapolis is where serious professionals find the technologies\, education\, and connections needed to thrive in the medtech community. \nMeet SenzaGen Business Development Director\, Joshua Schmidt at MD&M.\nTo book a meeting\, please email:  joshua.schmidt (at) senzagen.com
URL:https://senzagen.com/event/medical-design-manufacturing-mdm-minneapolis/
LOCATION:Minneapolis Convention Center\, United States
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2018/10/mdm_logo_0.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181015
DTEND;VALUE=DATE:20181019
DTSTAMP:20261008T192156
CREATED:20180911T084441Z
LAST-MODIFIED:20180918T211345Z
UID:17531-1539561600-1539907199@senzagen.com
SUMMARY:ESTIV 2018\, 20th International Congress on In Vitro Toxicology\, Berlin
DESCRIPTION:SenzaGen is proud to sponsor\, exhibit and present poster at the ESTIV conference\, 2018.\n\nThe conference emphasis will be specifically on how new technologies can strengthen the interpretation and application of in vitro methods in toxicological research and risk assessment. \nThe ESTIV conference will be the official launch of the new GARDair\, the first in vitro test for airway allergies. \nFind us in Booth #19\nPoster: GARDair – A novel assay for assessment of chemical respiratory sensitizers based on a genomic platform
URL:https://senzagen.com/event/20th-international-congress-on-in-vitro-toxicology-berlin-senzagen-is-proud-to-sponsor-exhibit-and-present-poster-at-the-estiv-conference-2018/
LOCATION:Berlin\, Germany
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2018/09/ESTIV_2018_Web_300x250px_.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181003
DTEND;VALUE=DATE:20181005
DTSTAMP:20261008T192156
CREATED:20180911T083913Z
LAST-MODIFIED:20180911T084923Z
UID:17527-1538524800-1538697599@senzagen.com
SUMMARY:The 7th Medicon Valley Inhalation Symposium – Future Opportunities of Inhalation 2018
DESCRIPTION:SenzaGen is proud to sponsor\, exhibit and present at MVIC’s Symposium\, MVIS\, 2018 \nDate: Wednesday the 3rd of October – Thursday the 4th of October 2018\nTime: Day 1: 09.00–18.00. Day 2: 09.00–13.00\nPlace: Medicon Village\, Lund\, Sweden \nPresentation\, Day 2: 09.25–09.50 \, Predictive Respiratory Toxicology with the GARD In-Vitro Testing Platform\, Dr Henrik Johansson\, SenzaGen AB
URL:https://senzagen.com/event/the-7th-medicon-valley-inhalation-symposium-future-opportunities-of-inhalation-2018/
LOCATION:Medicon Village\, Scheelevägen 2\, Lund\, Sweden
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2018/09/MVIC_symposium.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181002
DTEND;VALUE=DATE:20181003
DTSTAMP:20261008T192156
CREATED:20180911T083515Z
LAST-MODIFIED:20180911T085550Z
UID:17522-1538438400-1538524799@senzagen.com
SUMMARY:Understanding Biocompatibility of Medical Devices\, Medicon Village\, Lund
DESCRIPTION:SenzaGen are the hosts of this  Medicon Valley MedTech Network meeting. \nThe regulatory framework of the medical device industry is going through major changes and the complexity of the process is increasing due to new requirements and standards. All medical devices that come into physical contact with patients must be assessed for allergy. Therefore\, manufacturers must conduct biological safety evaluations before market approval. \nWelcome to join us at the next Medicon Valley MedTech Network meeting to learn more about ISO 10993* and the recent changes in the standard\, and understand how to make a biological evaluation of your medical device products.
URL:https://senzagen.com/event/understanding-biocompatibility-of-medical-devices-medicon-village-lund/
LOCATION:Medicon Village\, Scheelevägen 2\, Lund\, Sweden
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2018/09/Medicon-Valley-Medtech-Network_ny2.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180925
DTEND;VALUE=DATE:20180926
DTSTAMP:20261008T192156
CREATED:20180911T082843Z
LAST-MODIFIED:20180911T083151Z
UID:17510-1537833600-1537919999@senzagen.com
SUMMARY:North American Biocompability Summit\, Minneapolis\, US
DESCRIPTION:SenzaGen is participating at The North American Biocompatibility Summit.\nThe event will provide industry insights and expertise sharing on the biocompatibility of medical devices\, including the latest regulatory updates\, biological evaluation strategies and best practices that lead to successful biocompatibility programs.
URL:https://senzagen.com/event/north-american-biocompability-summit-minneapolis-us/
LOCATION:Minneapolis\, United States
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2018/09/nabs-logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180923
DTEND;VALUE=DATE:20180927
DTSTAMP:20261008T192156
CREATED:20180911T082419Z
LAST-MODIFIED:20180927T124556Z
UID:17506-1537660800-1538006399@senzagen.com
SUMMARY:EUSAAT\, Linz\, Austria
DESCRIPTION:EUSAAT\, the European Society for Alternatives to Animal Testing\, is the European 3Rs Society. EUSAAT is actively promoting the protection of experimental animals according to the 3Rs-Principle (refine – reduce – replace).
URL:https://senzagen.com/event/eusaat-linz-austria/
LOCATION:Linz\, Austria
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2018/05/logo_eusaat_web.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180920
DTEND;VALUE=DATE:20180922
DTSTAMP:20261008T192156
CREATED:20180911T082218Z
LAST-MODIFIED:20180911T083247Z
UID:17503-1537401600-1537574399@senzagen.com
SUMMARY:2nd International Conference on Alternative Methods for Cosmetics\, Beijing\, China
DESCRIPTION:SenzaGen will participate in the 2nd International Conference on Alternative Methods for Cosmetics in Beijing. A two day event organized by National Institutes for Food and Drug Control (NIFDC) \, the most prominent institutes for validation of new in vitro test methods for cosmetics in China.
URL:https://senzagen.com/event/2nd-international-conference-on-alternative-methods-for-cosmetics-beijing-china/
LOCATION:Beijing\, China
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2018/09/Beijing-conference-poster.jpg
END:VEVENT
END:VCALENDAR